Iterum Therapeutics Plc (ITRM) Stock Price, Quote & News

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 903 8354

Website: www.iterumtx.com

Address:

3 Dublin Landings, North Wall Quay, Dublin, Ireland

gogo66so Jan. 14 at 12:51 PM

$ITRM page 20 https://wa.kaiserpermanente.org/static/pdf/public/formulary/if-sg-2026.pdf?kp_shortcut_referrer=kp.org/wa/7formulary2026

0 · Reply

gogo66so Jan. 14 at 12:37 PM

$ITRM IDstewardship Year End Review 2025 TOP NEW POSTS IN 2025 Year in Review: Top Infectious Diseases Journal Articles From 2025 – 3,631 reads Five Interesting Things To Know About Sulopenem (Orlynvah) – 1,676 reads https://www.idstewardship.com/idstewardship-year-end-review-2025/

0 · Reply

gogo66so Jan. 14 at 12:15 PM

$ITRM page 10 https://medicaidpublications.dhss.delaware.gov/docs/DesktopModules/Bring2mind/DMX/API/Entries/Download?Command=Core_Download&EntryId=940&language=en-US&PortalId=0&TabId=94

0 · Reply

gogo66so Jan. 14 at 12:13 PM

$ITRM page 38 https://fm.formularynavigator.com/FBO/41/2026_Advanced_Control.pdf

0 · Reply

gogo66so Jan. 14 at 12:11 PM

$ITRM page 18 https://www.bcbsm.com/amslibs/content/dam/public/marketplace/2025-individual/documents/custom-select-drug-list/six-tier.pdf

0 · Reply

gogo66so Jan. 14 at 12:09 PM

$ITRM Page 341 https://www.denverhealthmedicalplan.org/sites/default/files/resources/document/MCD_CHP%20Prior%20Authorization%20criteria%201Q2026.pdf

0 · Reply

gogo66so Jan. 14 at 12:07 PM

$ITRM Page 4 https://www.caresource.com/documents/ar-pas-m-1135300-v-17-sum-of-form-changes-ar-passe_web.pdf

0 · Reply

gogo66so Jan. 14 at 11:52 AM

$ITRM Risk Factors for Treatment Failure in Patients with Uncomplicated Urinary Tract Infection 2026 Jan 11 Older age, higher BMI, lower creatinine clearance and the presence of Diabetes mellitus identified uUTI patients at increased risk for treatment failure. These variables, plus infection known or suspected to be resistant to one or more commonly prescribed oral antibiotic, may serve to guide clinicians when choosing empiric antibiotic therapy for adult women with uUTI. https://pmc.ncbi.nlm.nih.gov/articles/PMC12792308/

0 · Reply

gogo66so Jan. 14 at 11:45 AM

$ITRM We updated a couple of studies : Published: 11 January 2026 Conclusion The potent in vitro activity of sulopenem against this large collection of contemporary Enterobacterales clinical isolates from multiple infection types supports its use in the treatment of uncomplicated urinary tract infection, as well as its further clinical evaluation in the treatment of other common bacterial infections demonstrating resistant phenotypes. Disclosures Steven I. Aronin, MD, Iterum Therapeutics: Employee|Iterum Therapeutics: Stocks/Bonds (Public Company) Michael D. Huband, BS, Melinta Therapeutics: Advisor/Consultant|Melinta Therapeutics: Grant/Research Support Kelley A. Fedler, BS, Melinta Therapeutics: Grant/Research Support Michael Dunne, MD, Iterum Therapeutics: Board Member|Iterum Therapeutics: Employee|Iterum Therapeutics: Stocks/Bonds (Public Company) https://academic.oup.com/ofid/article/13/Supplement_1/ofaf695.1401/8421293?searchresult=1

1 · Reply

gogo66so Jan. 14 at 11:40 AM

$ITRM Iterum's Ongoing Stake: While Melinta handles commercial operations, Iterum remains the product's original developer and maintains its royalty obligations to Pfizer, the drug's original discoverer. Impact of the 2025 Acquisition When CorMedix acquired Melinta in late 2025, it inherited this commercial license agreement. CorMedix now uses Melinta’s existing acute care infrastructure to support both its own product, DefenCath, and Iterum’s Orlynvah

0 · Reply

Iterum Therapeutics Provides Business Update

Nov 14, 2025, 11:11 AM EST - 2 months ago

Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 2 months ago

Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:00 AM EST - 2 months ago

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

Oct 14, 2025, 8:30 AM EDT - 3 months ago

Iterum Therapeutics to Present Data at IDWeek 2025

Aug 20, 2025, 8:00 AM EDT - 5 months ago

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Aug 5, 2025, 4:58 PM EDT - 5 months ago

Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 2, 2025, 4:30 PM EDT - 6 months ago

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 7:00 AM EDT - 7 months ago

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

Jun 25, 2025, 7:00 AM EDT - 7 months ago

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

Jun 11, 2025, 7:00 AM EDT - 7 months ago

Iterum Therapeutics Announces Partnership for Commercialization Services

May 19, 2025, 7:00 AM EDT - 8 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note

May 13, 2025, 1:44 PM EDT - 8 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 8 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 9 months ago

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 30, 2025, 4:30 PM EDT - 9 months ago

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Apr 29, 2025, 8:00 AM EDT - 9 months ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Feb 7, 2025, 10:20 AM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 7:00 AM EST - 1 year ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 31, 2025, 8:00 AM EST - 1 year ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Nov 21, 2024, 8:30 AM EST - 1 year ago

Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 14, 2024, 1:14 PM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:00 AM EST - 1 year ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 10:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)

Oct 28, 2024, 5:00 AM EDT - 1 year ago

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 11:03 AM EDT - 1 year ago

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024

Oct 9, 2024, 5:00 PM EDT - 1 year ago

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 6, 2024, 5:30 PM EDT - 1 year ago

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 31, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 13, 2024, 9:49 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Jan 30, 2024, 7:00 AM EST - 2 years ago

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

gogo66so Jan. 14 at 12:51 PM

$ITRM page 20 https://wa.kaiserpermanente.org/static/pdf/public/formulary/if-sg-2026.pdf?kp_shortcut_referrer=kp.org/wa/7formulary2026

0 · Reply

gogo66so Jan. 14 at 12:37 PM

0 · Reply

gogo66so Jan. 14 at 12:15 PM

$ITRM page 10 https://medicaidpublications.dhss.delaware.gov/docs/DesktopModules/Bring2mind/DMX/API/Entries/Download?Command=Core_Download&EntryId=940&language=en-US&PortalId=0&TabId=94

0 · Reply

gogo66so Jan. 14 at 12:13 PM

$ITRM page 38 https://fm.formularynavigator.com/FBO/41/2026_Advanced_Control.pdf

0 · Reply

gogo66so Jan. 14 at 12:11 PM

$ITRM page 18 https://www.bcbsm.com/amslibs/content/dam/public/marketplace/2025-individual/documents/custom-select-drug-list/six-tier.pdf

0 · Reply

gogo66so Jan. 14 at 12:09 PM

$ITRM Page 341 https://www.denverhealthmedicalplan.org/sites/default/files/resources/document/MCD_CHP%20Prior%20Authorization%20criteria%201Q2026.pdf

0 · Reply

gogo66so Jan. 14 at 12:07 PM

$ITRM Page 4 https://www.caresource.com/documents/ar-pas-m-1135300-v-17-sum-of-form-changes-ar-passe_web.pdf

0 · Reply

gogo66so Jan. 14 at 11:52 AM

0 · Reply

gogo66so Jan. 14 at 11:45 AM

1 · Reply

gogo66so Jan. 14 at 11:40 AM

0 · Reply

gogo66so Jan. 14 at 11:38 AM

$ITRM Rabbit Holes: Strategic Partnership: Iterum developed sulopenem but lacked the extensive commercial infrastructure required for a large-scale U.S. launch. In June 2025, Iterum partnered with Melinta Therapeutics to leverage Melinta’s established sales force and market access capabilities. Melinta's Role: Melinta provides "end-to-end" commercialization services, including: Sales Force & Field Teams: Deploying representatives to target high-prescribing geographies for uncomplicated urinary tract infections (uUTIs). Market Access: Negotiating with Pharmacy Benefit Managers (PBMs) to secure formulary positioning; by early 2026, coverage reached over 40 million lives. Distribution: Managing the supply chain through major distributors like McKesson and Cencora

1 · Reply

daddyshere1984 Jan. 14 at 11:27 AM

$ITRM trash ..... Period...shit co..... Shitstain in my portfolio..... He definitely got us

0 · Reply

Alder77 Jan. 14 at 11:16 AM

$ITRM Unfortunately, this pile of shit won't budge, not even with a kick. The market has fully grasped the drug's low potential, the failed management, and the desperation of a cash-strapped company. I think we'll see the end of this farce in February. I don't think there's any news that can save us. Revenue will be ridiculous, as is obvious.

0 · Reply

DollerADay Jan. 14 at 2:06 AM

$ITRM Why is SP so low? It’s simple… The negative feedback loop is caused after shorts hit a micro cap hard dropping it below $1, and keeping it there until the non-compliance hits, which forces tutes to sell (by the letter of the law) like what happened in Q2 and Q3. SI is meaningless right now because they accomplished their goal at the expense of Fish and Co and retail. We wont fix this looming issue but it does set up the potential for the occasional win of biblical proportions for those that can survive.

3 · Reply

DollerADay Jan. 14 at 12:46 AM

$ITRM The Japan and China patents both locked in the last 60 days. A licensing deal would garner $20M -$100M each based on historical deals. Why has Fish and Co not done this and injected the non-dilutive lifeline (other than not caring about bleeding retail)? He didn’t because he built a defensive moat in current negotiations so BP can’t low ball them and risk receiving full global potential. IMO, we aren't in as dire of a position as the SP and miserable forum believes. An FDA response that stages the hybrid path will bring something many traders never see in their lifetime…

1 · Reply

RonBurgundysBroker Jan. 13 at 11:20 PM

$ITRM BREAKING NEWS: Clownman is in talks with Planet Fitness to get the drug in the vending machines inside the women’s locker rooms at all U.S. locations. Could be huge. Our reporter Amber is has called clownman for confirmation but just got his VM. We will continue to follow this breaking story.

2 · Reply

donman150 Jan. 13 at 10:58 PM

$ITRM Insane bruh!!! .000000000301c up. 🤬

2 · Reply

GatorMcKlusky Jan. 13 at 9:11 PM

$ITRM Oh thank you Sir for giving us that increase of 8 tenths of a penny! Thank you thank you thank you…

1 · Reply

onlyiknow Jan. 13 at 9:02 PM

$ITRM MM doinked it again to .3360 on the close for no apparent reason… Should have closed at .34 🤷‍♂️

0 · Reply

Steloco1 Jan. 13 at 8:49 PM

$ITRM $EVTV like $ ATON

0 · Reply

dnangel Jan. 13 at 8:18 PM

$ITRM Fishman scammers planning to raise additional 50 million shares but looking at volume and demand it will hardly generate 5 million.

1 · Reply

Mister_Wonderful Jan. 13 at 6:59 PM

$ITRM please end my misery aready and run like $EVTV

0 · Reply

Market Cap	17.48M
Revenue (ttm)	0.00
Net Income (ttm)	-24.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-2.88

Volume	442,900
Avg Vol	1,071,514
Day's Range	N/A - N/A
Shares Out	53.29M
Stochastic %K	55%
Beta	2.87
Analysts	Strong Sell
Price Target	$5.50